Egrifta SV
FDA-approved GHRH analog for HIV-associated lipodystrophy. Stimulates endogenous GH, reduces visceral adipose tissue ~15%. Off-label aesthetic body contouring potential.
Mimics GHRH at pituitary somatotroph receptors → increased GH synthesis and secretion → elevated IGF-1 → enhanced lipolysis, reduced visceral adiposity.
2mg SC daily (FDA label). Off-label similar dosing for visceral fat reduction.
Tesamorelin reduces VAT in HIV lipodystrophy
Tesamorelin vs GLP-1 in visceral fat
Refrigerate at 2-8°C. Reconstitute with provided diluent. Use within 24 hours of reconstitution.